Emcure Pharma IPO Details, Date, Allotment

Emcure Pharma IPO: Emcure Pharmaceuticals Limited IPO is a book-built issue, which includes a fresh issue worth Rs 800 crore and an offer for sale of 1.14 crore shares.

The Emcure Pharma IPO will be open for subscription from July 3, 2024, to July 5, 2024. The allotment of shares is expected to be finalized on July 8, 2024. Emcure Pharma’s shares are planned to be listed on the BSE and NSE, with the tentative listing date set for July 10, 2024.

Source from Emcure Pharma IPO RHP

Emcure Pharma IPO Details

Emcure Pharma IPO Date

• Emcure Pharma IPO Open Date: July 3, 2024
• IPO Close Date: July 5, 2024
• Emcure Pharma IPO allotment: July 8, 2024
• Refunds: July 9, 2024
• Shares Credit to Demat: July 9, 2024
• Emcure Pharma IPO Listing Date: July 10, 2024

Lot Size

Here is the table based on the provided information:

Please note:

• “B-HNI (Min)” continues from Lot 71 onwards.
• Shares and Amount ranges are provided based on the minimum and maximum values given.
• The Amount range for “B-HNI (Min)” is not fully specified due to the lack of specific maximum Lot and Share values provided in the original data.

Emcure Pharma IPO GMP (Grey Market Premium)

If you want to know Emcure Pharma IPO GMP (Grey Market Premium) then please visit our IPO GMP section and get daily updates on grey market premium. We update here all IPOs GMP.

Emcure Pharma IPO Subscription Status

Emcure Pharma IPO subscription starts on July 3, 2024, To get live IPO subscription status data go to our IPO Subscription section and see any ongoing IPO Subscription Status.

Emcure Pharma IPO Allotment Status

To check Emcure Pharma’s IPO allotment status go to the IPO registrar website ”Link Intime India Private Limited” or go to IPO Allotment>>.
You can find here any IPO allotment status. Following some stapes.

1. Go to the Link given above.
2. Select the IPO Name
3. Enter your PAN/ DP ID/ Application No
4. Submit details and get the allotment status.

Know About Company

Emcure Pharmaceuticals Limited was founded in 1981, Emcure Pharmaceuticals Limited is an Indian company that develops, manufactures, and sells a wide range of pharmaceutical products globally.

Ranked 13th in domestic sales among Indian pharmaceutical companies for the MAT (Moving Annual Total) ending September 2023, Emcure holds a significant position in the market. It also ranks 4th in market share in its covered markets during the same period. Notably, Emcure leads in the gynaecology and HIV antiviral therapeutic areas for the MAT ending September 2023.

For the six months ending September 30, 2023, and the Financial Year 2023, sales in India made up 50.84% and 53.16% of Emcure’s total revenue, respectively. The company’s domestic sales grew at a compound annual growth rate (CAGR) of 10.80% from September 2019 to September 2023, outperforming the overall Indian pharmaceutical market.

As of September 30, 2023, Emcure employed 552 scientists and operated five research facilities in India. The company filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. Emcure has 201 granted patents, 33 pending patent applications, and has submitted 102 drug master files.

Emcure Pharmaceuticals operates 13 manufacturing facilities across India. These facilities produce a variety of pharmaceutical and biopharmaceutical products, including tablets, liquids, injectables, and complex ingredients like chiral molecules, iron molecules, and cytotoxic substances.

Objects of the Issue

1. Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the Company; and
2. General corporate purposes.

Promoters Holding

Satish Mehta and Sunil Mehta are the promoters of the company. Pre-issue shareholding: 98.90%

Emcure Pharmaceuticals Limited Financial Report

Between the financial years ending March 31, 2023, and March 31, 2024, Emcure Pharmaceuticals Limited saw a revenue increase of 11.33%, while the profit after tax (PAT) decreased by 6.1%.

KPI Of Emcure Pharmaceuticals Limited

In the financial year ending March 31, 2024, Emcure Pharmaceuticals Limited’s revenue from Indian operations accounted for 48.28%, while international sales contributed 51.72%. The EBITDA for the year was ₹1,276.78 crore, with an EBITDA margin of 19.01%. The PAT for the year was ₹527.58 crore, resulting in a PAT margin of 7.86%. The return on capital employed (RoCE) was 19.37%.

Peer Group

• Dr. Reddy’s Laboratories Limited
• Cipla Limited
• Alkem Laboratories Limited
• Torrent Pharmaceuticals Limited
• Mankind Pharma Limited
• Abbott India Limited (Standalone)
• J. B. Chemicals & Pharmaceuticals Limited

Emcure Pharmaceuticals Limited IPO Registrar

Link Intime India Private Limited
C-101, 1st Floor, 247 Park
Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai 400 083
Maharashtra, India
Tel: + 91 810 811 4949
E-mail: emcure.ipo@linkintime.co.in
Website: www.linkintime.co.in

Emcure Pharmaceuticals Limited IPO Lead Manager

• Kotak Mahindra Capital Company Limited
• Axis Capital Limited
• Jefferies India Private Limited
• J. P. Morgan India Private Limited

Emcure Pharmaceuticals Limited Contact

Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune -411 057
Phone: +91 20 3507 0033
Email: investors@emcure.co.in
Website: https://www.emcure.com/

Emcure Pharmaceuticals Limited IPO Application Form PDF

To download the Emcure Pharmaceuticals Limited IPO application form Check out the Application Form Download ASBA IPO Forms PDF.

FAQs